LAB/B: Mexico recovery lifts sales, but investment weighs on margins and cash
LAB/B sales returned to growth in the third quarter as Mexico recovers, while investment kept EBITDA margin under pressure, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the company's third-quarter sales grew again as Mexico's economy continues to recover. However, an ongoing investment program kept pressure on the EBITDA margin.
Net income was partly supported by a one-off foreign exchange gain. Cash flow was strong, although working capital rose temporarily, which affected cash conversion.
why it matters
Investors should weigh two points: sales growth in Mexico points to resilient regional demand, while investment and working capital pressure on margins lowers the quality of earnings. The one-off currency gain makes the headline profit less indicative of current operations. Comparing this quarter with earlier periods and with peer reports will help gauge the impact on the stock.
tags
instruments
sources
- LAB/B: Mexico's recovery advanced, while investment and working capital weighed on margins and cash conversion — TradingView, 22 October 2026 at 19:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗